BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37779132)

  • 1. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.
    Murthy V; Appiah-Kubi E; Nguyen K; Thin P; Hotta M; Shen J; Drakaki A; Rettig M; Gafita A; Calais J; Sonni I
    Eur J Hybrid Imaging; 2023 Oct; 7(1):18. PubMed ID: 37779132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
    Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
    J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.
    Sonni I; Gafita A; Unterrainer LM; Alano RM; Lira S; Shen J; Drakaki A; Grogan T; Rettig MB; Czernin J; Calais J
    EJNMMI Res; 2023 Oct; 13(1):95. PubMed ID: 37902861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Hoberück S; Löck S; Winzer R; Zöphel K; Froehner M; Fedders D; Kotzerke J; Hölscher T
    EJNMMI Res; 2020 Nov; 10(1):135. PubMed ID: 33159278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
    Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
    J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
    Özülker T; Özülker F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flare on [
    Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
    Afshar-Oromieh A; Debus N; Uhrig M; Hope TA; Evans MJ; Holland-Letz T; Giesel FL; Kopka K; Hadaschik B; Kratochwil C; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2045-2054. PubMed ID: 29980832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection Rate of
    Brumberg J; Beckl M; Dierks A; Schirbel A; Krebs M; Buck A; Kübler H; Lapa C; Seitz AK
    Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33217931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of androgen deprivation therapy on
    Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
    Deijen CL; Vrijenhoek GL; Schaake EE; Vogel WV; Moonen LMF; Pos FJ; van der Poel HG; Borst GR
    Clin Transl Radiat Oncol; 2021 Sep; 30():1-6. PubMed ID: 34278008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
    Kesler M; Druckmann I; Levine C; Kuten J; Yossepowitch O; Even-Sapir E
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578990
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with
    Ettala O; Malaspina S; Tuokkola T; Luoto P; Löyttyniemi E; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):665-673. PubMed ID: 31879814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.